Biointron

Biointron is a Shanghai-based biotechnology startup that has been operating since 2012. The company is certified to ISO 9001:2015 and is a CRO supplier for antibody discovery and expression. With a focus on accelerating the antibody discovery process, Biointron offers a range of services including VHH production, hybridoma sequencing, antibody humanization, affinity maturation, and single B cell screening. The company has a global commercialization reauthorization for ECACC's CHO-K1 cell line and meets international multicenter requirements. Notably, several of Biointron's projects have entered the international multicenter clinical stage.

Recently, the company received a significant CNY500.00M Series B investment on 31 August 2022 from a group of prominent investors including Joy Capital, Gaorong Capital, LYFE Capital, October Capital, ALAN Asset Management Co., Ltd, Binfu Capital, Co-Stone Venture Capital, Tianhui Chuangtou, Jiangsu High Investment, and CS Capital. This investment is a testament to the potential and promise of Biointron's innovative approach to expedite the antibody discovery process.

Biointron's commitment to high-technology solutions and international standards, as well as its extensive client base of 1,500+ pharmaceutical companies across 20 countries, positions the company as a key player in the biotechnology industry. For more detailed information, visit Biointron's official website at www.biointron.com or reach out to them at [email protected].